Recent changes to the European Pharmacopoeia Monograph has left many Pharmaceutical companies unclear as to which process to adopt in water for injection (WFI) production.
James Steptoe, Veolia Water Technologies, has delivered a webinar on 'Water for injection production with a Reverse Osmosis-based system'. James has reviewed these changes and compared the different approaches available for WFI production.
What was covered?
An overview of WFI
WFI - Quality of different purified water standards
Recent changes to the European Pharmacopoeia Monograph and the impact on the market
Distillation versus Reverse Osmosis - the benefits and implications of both methods
Making the right choice of WFI production methods - finding the right balance between cost and risk
Traditional distillation versus alternative purification processes
With recent regulatory changes made by the European Pharmacopoeia, we've answered the key questions facing the market at a time where change is possible. Decision makers are tasked with the option of continuing with traditional methods or turning to newly approved techniques as their preferred choice in providing pure distilled water for injections.
Orion: purified water production for the Pharmaceutical market
Orion is a skid-mounted multi-technology system. It offers softening, reverse osmosis and continuous electrodeionisation (CEDI) technologies that can be fully or partially hot water sanitised. It is ideal for use as a pharmaceutical water system for the generation of purified water.